All In Biotech

Drug Trial Radar · NCT04116502

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Oct 25, 2019

Primary completion

Oct 31, 2028

Study completion Apr 1, 2030

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis; MPN Voice; National Cancer Institute, France
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.

Conditions

  • Polycythemia Vera

Interventions

  • RuxolitinibDrug

    10mg of ruxolitinib twice daily (bd)

  • HydroxycarbamideDrug

    Via standard hospital mechanisms

  • Interferon-AlphaDrug

    Any formulation, via standard hospital mechanisms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (EFS)Time frame: the time from randomisation to the date of the first major thrombosis/haemorrhage, death,transformation to Myelodysplastic Syndromes, Acute Myeloid Leukaemia or Post-polycythemia Vera Myelofibrosis, if within the ~3 year trial period

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • Royal United Hospital

    Bath, United Kingdom · Recruiting

  • Belfast City Hospital

    Belfast, United Kingdom · Recruiting

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom · Recruiting

  • Blackpool Victoria Hospital

    Blackpool, United Kingdom · Recruiting

  • Glan Clwyd Hospital

    Bodelwyddan, United Kingdom · Recruiting

  • Royal Bournemouth Hospital

    Bournemouth, United Kingdom · Recruiting

  • Southmead Hospital

    Bristol, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • Kent and Canterbury Hospital

    Canterbury, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • St Richard's Hospital

    Chichester, United Kingdom · Recruiting

  • Colchester Hospital

    Colchester, United Kingdom · Recruiting

  • Castle Hill Hospital

    Cottingham, United Kingdom · Recruiting

  • University Hospital

    Coventry, United Kingdom · Recruiting

  • Russells Hall Hospital

    Dudley, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • Royal Devon and Exeter Hospital

    Exeter, United Kingdom · Recruiting

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom · Recruiting

  • Calderdale Royal Hospital

    Halifax, United Kingdom · Active not recruiting

  • Huddersfield Royal Infirmary

    Huddersfield, United Kingdom · Active not recruiting

  • Raigmore Hospital

    Inverness, United Kingdom · Recruiting

  • Ipswich Hospital

    Ipswich, United Kingdom · Recruiting

  • Kettering General Hospital

    Kettering, United Kingdom · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • St John's Hospital

    Livingston, United Kingdom · Recruiting

  • University College Hospital

    London, United Kingdom · Recruiting

  • Guy's Hospital

    London, United Kingdom · Recruiting

  • St George's Hospital

    London, United Kingdom · Recruiting

  • Wythenshawe Hospital

    Manchester, United Kingdom · Recruiting

  • Arrowe Park Hospital

    Metropolitan Borough of Wirral, United Kingdom · Recruiting

  • The James Cook University Hospital

    Middlesbrough, United Kingdom · Recruiting

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Royal Gwent Hospital

    Newport, United Kingdom · Recruiting

  • North Tyneside General Hospital

    North Shields, United Kingdom · Recruiting

  • Northampton General Hospital

    Northampton, United Kingdom · Recruiting

  • Norfolk and Norwich University Hospital

    Norwich, United Kingdom · Recruiting

  • Nottingham City Hospital

    Nottingham, United Kingdom · Recruiting

  • George Eliot Hospital

    Nuneaton, United Kingdom · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.